ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Alpha-1 15%

Its studies are mostly in alpha 1-Antitrypsin Deficiency, led by Grifols.

Furthest: phase 3, since Apr 21, 20262 company-led studies, 1 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grifols21 open or runningphase 3since Apr 21, 2026Jan 20, 2021Sep 30, 2027phase 3 · NCT07555483

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2021First study: phase 2 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT04722887 · 17 enrolled · United States
  2. Apr 21, 2026Phase 3 study in alpha 1-Antitrypsin DeficiencyPhase 3 reachedNCT07555483 · 40 planned · United States, Denmark, Germany and more

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in alpha 1-Antitrypsin DeficiencyNCT07555483

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07555483alpha 1-Antitrypsin Deficiency · United States, Denmark, Germany and more3RecruitingSep 30, 202740
NCT04722887alpha 1-Antitrypsin Deficiency · United States2CompletedAug 1, 202517

How it is read

Names in the registry

  • “Alpha-1 15%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.